NCT07641010Not yet recruitingPhase 1
A Prospective, Multicenter, Randomized Controlled Clinical Study of Camrelizumab in Combination With Ivarmacitinib as First-line Treatment for Pediatric Classical Hodgkin Lymphoma
Shanghai Jiao Tong University School of Medicine1 site in 1 country112 target enrollmentStarted: June 30, 2026Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 112
- Locations
- 1
Study Overview
Brief Summary
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
Detailed Description
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 6 Years to 18 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 6-18 years, male or female;
- •Histologically confirmed classic Hodgkin lymphoma;
- •Newly diagnosed, previously untreated patients;
- •Subjects must have at least one measurable lesion, defined as: a lymph node lesion with the longest diameter >1.5 cm on CT cross-sectional imaging; or an extranodal lesion with the longest diameter >1.0 cm;
- •ECOG performance status (PS) 0-2;
- •Life expectancy ≥3 months;
- •All screening laboratory tests must be performed as required by the protocol and within 7 days prior to enrollment. The laboratory values obtained at screening must meet the following criteria:
- •Hematology (without blood transfusion, G-CSF, or medication to correct abnormalities within 14 days prior to screening):
- •Hemoglobin (Hb) ≥70 g/L;
- •Absolute neutrophil count (ANC) ≥0.5×10⁹/L;
- •Platelet count (PLT) ≥30×10⁹/L;
- •Biochemistry:
- •Direct bilirubin (DBIL) <2 × upper limit of normal (ULN);
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN;
- •Serum creatinine clearance ≥40 mL/min;
- •The patient or his/her legal guardian has signed the informed consent form (ICF) and voluntarily agrees to participate in this study.
Exclusion Criteria
- •Histopathologically confirmed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL);
- •Prior anti-tumor therapy for classic Hodgkin lymphoma (cHL);
- •Patients with central nervous system (CNS) involvement by lymphoma;
- •Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption;
- •Presence of any active, known, or suspected autoimmune disease (subjects who are in a stable condition and do not require systemic immunosuppressive therapy are permitted to enroll);
- •Use of immunosuppressive agents, including systemic corticosteroids, within 14 days prior to study drug administration (use of ≤10 mg/day prednisone or equivalent is permitted);
- •History of other malignancies within the past 5 years;
- •Severe cardiac dysfunction with ejection fraction (EF) <50%, or severe cardiac arrhythmia;
- •Any arterial thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack;
- •Active hepatitis B or hepatitis C infection;
- •History of stroke or intracranial hemorrhage within the past 6 months;
- •Known history of human immunodeficiency virus (HIV) positivity.
Investigators
Shuhong Shen
Chair of hematology oncology department of SCMC
Shanghai Jiao Tong University School of Medicine
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 3
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNCT07432087Yue He, MD246
Recruiting
Phase 2
Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNCT07622797The First Affiliated Hospital of Henan University of Science and Technology164
Recruiting
Phase 3
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCCNCT07267806Linhui Peng326
Recruiting
Phase 2
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and ImmunotherapyNCT07594015University of Miami46
Recruiting
Phase 2
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric CancerGastric CancerNCT07320586Shandong Tumor Hospital40